Compare OPTT & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTT | BRNS |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 24.1M |
| IPO Year | 2006 | 2021 |
| Metric | OPTT | BRNS |
|---|---|---|
| Price | $0.30 | $0.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.50 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 3.1M | 17.7K |
| Earning Date | 03-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,861,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $221.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $0.29 | $0.51 |
| 52 Week High | $0.90 | $2.91 |
| Indicator | OPTT | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 50.97 |
| Support Level | N/A | $0.65 |
| Resistance Level | $0.40 | $0.75 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 0.13 | 38.72 |
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.